A comprehensive approach to the prevention of bronchopulmonary dysplasia

  title={A comprehensive approach to the prevention of bronchopulmonary dysplasia},
  author={Amir Kugelman and Manuel Durand},
  journal={Pediatric Pulmonology},
The current bronchopulmonary dysplasia (BPD) is seen in infants born extremely premature, with less severe respiratory distress syndrome (RDS) and who received prenatal steroids—“new BPD”. The pathophysiology of BPD is based on an impairment of lung maturation with prenatal and postnatal multi‐hit insults and genetic susceptibility. This multifactorial pathophysiology of BPD suggests that no single “magic bullet” will prevent it. Thus, to avoid BPD we need to implement a complex and… 
Advances in bronchopulmonary dysplasia
Current and potential future therapeutic strategies for Bronchopulmonary dysplasia are reviewed and stem cell-based therapies are a new investigational strategy showing promise for the prevention or treatment of BPD.
Bronchopulmonary dysplasia.
Although the clinical presentation now differs from its original description, BPD continues to be one of the most common complications of premature infants and presents several challenges to clinicians.
Nutrition and bronchopulmonary dysplasia
  • C. Dani, C. Poggi
  • Medicine
    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
  • 2012
Early nutrition support and careful adjustment of parenteral nutrition and appropriate enteral feeding selection may enhance the growth and contribute a better neurodevelopment in patients with bronchopulmonary dysplasia or BPD.
Bronchopulmonary Dysplasia in Premature Infants with Very Low Birth Weight: A Single Centre Retrospective Study in China
It is suggested that low GA was the most important risk factor for BPD, DEX reduced oxygen dependency but decreased weight gain, and the oxygen requirement had significantly reduced compared to the week prior to treatment.
Future treatment for BPD
Targeting a treatment that will help repair the lungs, restore architecture, and promote lung development for infants who are developing chronic lung disease is exactly what is necessary.
News on neonatal respiratory research
The role of the sustained lung inflation procedure in the delivery room, the development of new exogenous surfactant preparations, the effectiveness of nasal high frequency ventilation (nHFV), and the treatment of patent ductusarteriosus with paracetamol are reported on.
Optimization of Airway Medications in the Infant
The most prominent airway medication, surfactant for respiratory distress syndrome, will be discussed elsewhere in this issue of Neonatology, and indications such as the prevention of bronchopulmonary dysplasia are the focus of a large multicenter international trial.
Inhaled Corticosteroids for Bronchopulmonary Dysplasia: A Meta-analysis
Very preterm infants appear to benefit from ICs with reduced risk for BPD and no effect on death, other morbidities, or adverse events.
Prevalence and factors associated with bronchopulmonary dysplasia in a referral hospital in Minas Gerais , Brazil Prevalência e fatores associados à displasia broncopulmonar em hospital de referência para microrregião de Minas Gerais
Despite substantial changes in incidence, risk factors and severity after the introduction of new therapies and mechanical ventilation techniques, BPD remains common and knowledge of factors that are associated with BPD development contributes to its prevention.


Emerging drugs for the prevention of bronchopulmonary dysplasia.
Systemically administered corticosteroids, if given in the first 2 weeks, do significantly reduce BPD but have serious side effects, and further investigation is needed to identify the safest dosage regimen.
Pulmonary function outcomes in bronchopulmonary dysplasia through childhood and into adulthood: implications for primary care.
The pulmonary function outcomes resulting from BPD through later childhood and young adulthood are reviewed, which has been coined the 'new' BPD.
Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia
High-dose dexamethasone (0.5 mg/kg per day) does not seem to confer additional therapeutic benefit over lower doses and is not recommended, and evidence is insufficient to make a recommendation regarding other glucocorticoid doses and preparations.
Inhaled drugs for the prevention and treatment of bronchopulmonary dysplasia
Bronchopulmonary dysplasia (BPD) is one of the most common long‐term complications and treatment challenges in preterm infants. Theoretically, inhaled corticosteroids may suppress pulmonary
Postnatal corticosteroids for bronchopulmonary dysplasia.
  • A. Jobe
  • Medicine
    Clinics in perinatology
  • 2009
[Bronchopulmonary dysplasia].
A wide-ranging review of the literature on bronchopulmonary dysplasia is presented, covering new definitions, pathophysiology, prevention, treatment, prognosis and progression.
Bronchopulmonary dysplasia – prevalence, severity and predictive factors in a national cohort of extremely premature infants
Aim:  To study prevalence and predictive factors of bronchopulmonary dysplasia (BPD) in a cohort of preterm infants with a high incidence of prenatal steroid and surfactant treatment.
Does bronchopulmonary dysplasia contribute to the occurrence of cerebral palsy among infants born before 28 weeks of gestation?
Combined treatment with both MV and supplemental oxygen at 36 weeks PMA strongly predicts the more common bilateral CP phenotypes, and BPD without MV at 36 Weeks PMA was not significantly associated with any form of CP.
The role of nutrition in the prevention and management of bronchopulmonary dysplasia.
Close post discharge follow up of infants with BPD is necessary to monitor growth and to ensure intake of sufficient protein and calories.